|
Fiscal Period: December
|
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Capitalization1 |
449 | 321 | 171 | 874 | 347 | - | - |
Enterprise Value (EV)1 |
306 | 193 | -0,43 | 673 | 324 | 351 | 166 |
P/E ratio |
-2,13x | -3,19x | -1,41x | -13,5x | -3,07x | -2,98x | -3,39x |
Yield |
- | - | - | - | - | - | - |
Capitalization / Revenue |
378x | 73,6x | 42,3x | 18,1x | 18,0x | 24,6x | 54,9x |
EV / Revenue |
258x | 44,3x | -0,11x | 14,0x | 16,9x | 24,9x | 26,3x |
EV / EBITDA |
-4,97x | -2,08x | 0,00x | -9,77x | -2,69x | -2,45x | -0,98x |
Price to Book |
- | 2,43x | - | - | - | - | - |
Nbr of stocks (in thousands) |
29 038 | 35 806 | 43 307 | 67 988 | 73 007 | - | - |
Reference price (USD) |
15,5 | 8,97 | 3,94 | 12,9 | 4,75 | 4,75 | 4,75 |
Announcement Date |
03/28/2019 | 03/11/2020 | 03/11/2021 | 03/10/2022 | - | - | - |
1 USD in Million |
|
|
Income Statement Evolution (Annual data) |
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Net sales1 |
- | 1,19 | 4,37 | 4,04 | 48,2 | 19,2 | 14,1 | 6,31 |
EBITDA1 |
-39,8 | -61,6 | -93,2 | -99,4 | -68,9 | -120 | -143 | -169 |
Operating profit (EBIT)1 |
- | -65,6 | -97,9 | -106 | -75,2 | -124 | -142 | -157 |
Operating Margin |
- | -5 525% | -2 244% | -2 626% | -156% | -648% | -1 010% | -2 487% |
Pre-Tax Profit (EBT)1 |
- | -64,8 | -94,4 | -105 | -75,1 | -123 | -139 | -147 |
Net income1 |
-41,4 | -64,8 | -94,4 | -105 | -75,1 | -123 | -139 | -147 |
Net margin |
- | -5 457% | -2 163% | -2 609% | -156% | -642% | -984% | -2 332% |
EPS2 |
-20,7 | -7,26 | -2,81 | -2,79 | -0,95 | -1,55 | -1,59 | -1,40 |
Dividend per Share |
- | - | - | - | - | - | - | - |
Announcement Date |
05/04/2018 | 03/28/2019 | 03/11/2020 | 03/11/2021 | 03/10/2022 | - | - | - |
1 USD in Million 2 USD |
|
|
Income Statement Evolution (Quarterly data) |
|
Fiscal Period: December
|
2020 Q1 |
2020 Q2 |
2020 Q3 |
2020 Q4 |
2021 Q1 |
2021 Q2 |
2021 Q3 |
2021 Q4 |
2022 Q1 |
2022 Q2 |
2022 Q3 |
2022 Q4 |
2023 Q1 |
2023 Q2 |
2023 Q3 |
Net sales1 |
1,26 | 0,49 | 0,94 | 1,35 | 39,7 | 2,84 | 2,61 | 3,06 | 7,19 | 5,47 | 3,26 | 3,28 | 3,83 | 3,87 | 4,55 |
EBITDA |
-25,0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating profit (EBIT)1 |
-26,7 | -26,1 | -26,1 | -27,1 | 7,90 | -25,2 | -28,2 | -29,8 | -29,0 | -29,7 | -32,7 | -33,1 | -36,8 | -39,3 | - |
Operating Margin |
-2 113% | -5 340% | -2 784% | -2 014% | 19,9% | -885% | -1 077% | -972% | -403% | -542% | -1 003% | -1 010% | -960% | -1 016% | - |
Pre-Tax Profit (EBT)1 |
-26,2 | -25,9 | -26,1 | -27,2 | 7,92 | -25,1 | -28,1 | -29,8 | -28,9 | -29,5 | -32,2 | -32,6 | - | - | - |
Net income1 |
-26,2 | -25,9 | -26,1 | -27,2 | 7,92 | -25,1 | -28,1 | -29,8 | -28,9 | -29,5 | -32,2 | -32,6 | - | - | - |
Net margin |
-2 077% | -5 301% | -2 777% | -2 015% | 20,0% | -884% | -1 076% | -972% | -402% | -539% | -989% | -995% | - | - | - |
EPS2 |
-0,71 | -0,69 | -0,69 | -0,69 | 0,10 | -0,33 | -0,36 | -0,36 | -0,34 | -0,34 | -0,42 | -0,42 | -0,48 | -0,46 | -0,44 |
Dividend per Share |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date |
05/07/2020 | 08/05/2020 | 11/05/2020 | 03/11/2021 | 05/06/2021 | 08/05/2021 | 11/03/2021 | 03/10/2022 | 05/05/2022 | 08/04/2022 | - | - | - | - | - |
1 USD in Million 2 USD |
|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Net Debt1 |
- | - | - | - | - | - | 4,59 | - |
Net Cash position1 |
- | 143 | 128 | 171 | 202 | 23,0 | - | 181 |
Leverage (Debt / EBITDA) |
- | 2,31x | 1,37x | 1,72x | 2,93x | 0,19x | -0,03x | 1,07x |
Free Cash Flow1 |
- | -43,8 | -101 | -92,6 | -123 | -133 | -161 | -188 |
ROE (Net Profit / Equities) |
- | - | - | - | - | - | - | - |
Shareholders' equity1 |
- | - | - | - | - | - | - | - |
ROA (Net Profit / Asset) |
- | - | - | - | - | - | - | - |
Assets1 |
- | - | - | - | - | - | - | - |
Book Value Per Share |
- | - | 3,70 | - | - | - | - | - |
Cash Flow per Share |
-17,5 | -4,28 | -2,53 | - | - | - | - | - |
Capex |
11,5 | 5,66 | 16,2 | - | - | - | - | - |
Capex / Sales |
- | 477% | 371% | - | - | - | - | - |
Announcement Date |
05/04/2018 | 03/28/2019 | 03/11/2020 | 03/11/2021 | 03/10/2022 | - | - | - |
1 USD in Million |
|
| |
|
|
AstraZeneca : invests in Imperial's self-amplifying RNA technology with eye on future drugs |
Capitalization (USD) |
346 782 879 |
Net sales (USD) |
48 214 000 |
Number of employees |
193 |
Sales / Employee (USD) |
249 813 |
Free-Float |
97,0% |
Free-Float capitalization (USD) |
336 497 880 |
Avg. Exchange 20 sessions (USD) |
4 895 954 |
Average Daily Capital Traded |
1,41% |
|